Race-dependent association of clinical trial participation with improved outcomes for high-risk prostate cancer patients treated in the modern era.
Prostate Cancer Prostatic Dis
; 26(3): 625-627, 2023 09.
Article
em En
| MEDLINE
| ID: mdl-36966268
ABSTRACT
It is unclear whether cancer patients enrolled in clinical trials have improved outcomes compared with non-study patients. We compared prostate cancer-specific mortality (PCSM) in patients in a real-world setting (SEER-Medicare database) versus on a trial (NRG/RTOG 0521). The 7-year freedom from PCSM was superior in trial patients (92.4% vs. 88.1%, sHR = 1.77 [95% CI 1.05-2.97], P = 0.03). Black trial patients had significantly superior freedom from PCSM than Black real-world patients (sHR 6.52, 95% CI 1.43-29.72, P = 0.02), which was not seen among non-Black patients. Trial patients may have improved outcomes, and racial disparities are accentuated in the real world.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Neoplasias da Próstata
Tipo de estudo:
Etiology_studies
/
Risk_factors_studies
Limite:
Aged
/
Humans
/
Male
País como assunto:
America do norte
Idioma:
En
Ano de publicação:
2023
Tipo de documento:
Article